Current Opinion in Oncology最新文献_第7页

Treatment approaches for older Hodgkin lymphoma patients. 老年霍奇金淋巴瘤患者的治疗方法。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-09-01 Epub Date: 2024-06-20 DOI: 10.1097/CCO.0000000000001071

Paul J Bröckelmann

{"title":"Treatment approaches for older Hodgkin lymphoma patients.","authors":"Paul J Bröckelmann","doi":"10.1097/CCO.0000000000001071","DOIUrl":"10.1097/CCO.0000000000001071","url":null,"abstract":"Purpose of review: Hodgkin lymphoma (HL) occurs at two age peaks around 25 and 60 years of age. Due to varying fitness and co-morbidities older patients are a heterogeneous group that has relatively poor treatment outcomes. The evolving therapeutic landscape for older HL is summarized herein.Recent findings: Due to lack of data from larger trials and approval of novel drugs, first-line treatment of limited-stage HL (i.e. early-stage favourable and unfavourable) remains largely A(B)VD and radiotherapy based. For patients with advanced-stage HL, the anti-CD30 antibody-drug conjugate brentuximab vedotin is approved in combination with AVD chemotherapy (BV-AVD). Due to toxicities such as febrile neutropenia or polyneuropathy and lack of improvement in progression-free and overall survival in the older subgroup, fully concomitant BV-AVD is however not used widely. More recently, promising early data was reported with the combination of nivolumab and AVD (N-AVD) in patients >60 years with advanced-stage HL. Second-line treatment depends on fitness and might include high-dose chemotherapy and autologous stem-cell transplantation for selected patients. For unfit or multiply relapsed patients, anti-PD1 antibodies are the preferred treatment option.Summary: The increasing number of older HL patients constitutes a therapeutic challenge despite recent advances and the increased usage of targeted agents.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"353-359"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of sentinel lymph node biopsy with indocyanine green and site of injection in endometrial cancer. 吲哚菁绿前哨淋巴结活检在子宫内膜癌中的作用及注射部位。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-09-01 Epub Date: 2024-07-18 DOI: 10.1097/CCO.0000000000001075

Diego Raimondo, Antonio Raffone, Alberto Aguzzi, Linda Bertoldo, Renato Seracchioli

{"title":"Role of sentinel lymph node biopsy with indocyanine green and site of injection in endometrial cancer.","authors":"Diego Raimondo, Antonio Raffone, Alberto Aguzzi, Linda Bertoldo, Renato Seracchioli","doi":"10.1097/CCO.0000000000001075","DOIUrl":"https://doi.org/10.1097/CCO.0000000000001075","url":null,"abstract":"Purpose of review: The aim of the present narrative review is to summarize the state of art on sentinel lymph node biopsy (SLNB) in endometrial cancer, with a special focus on indocyanine green (ICG) as adopted tracer.Recent findings: Over the years, the surgical nodal staging in patients with endometrial cancer has been intensively investigated. Traditionally, systematic pelvic and para-aortic lymphadenectomy represented the gold standard surgical treatment to assess nodal involvement of the tumor. Through the last two decades, SLNB has gradually replaced lymphadenectomy as a more targeted procedure. A great heterogeneity of tracers and injection techniques have been proposed to perform SLNB. However, no universally accepted recommendations are still available.Summary: SLNB has nowadays almost replaced pelvic lymphadenectomy in low-risk endometrial cancers, offering a better safety profile while being related to a comparable nodal involvement sensitivity. Currently, ICG is considered to be the most used tracer among others. Different injection sites have been proposed, with different detection features. While ICG cervical injection is nowadays the suggested technique for SLNB, noncervical injection techniques, such as hysteroscopic and combined procedures, seem to have a better accuracy in para-aortic nodal assessment, which have a role in high-risk endometrial cancers.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":"36 5","pages":"383-390"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diligent use of MedDRA terminology and preferred term selection in safety reports of clinical trials. 在临床试验的安全性报告中认真使用 MedDRA 术语和首选术语。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI: 10.1097/CCO.0000000000001056

Martin F Fey, Seamus O'Reilly, Ahmad H Awada, John Crowley, Karen A Gelmon

引用次数: 0

Impact of sentinel node implementation in gynecologic cancers. 在妇科癌症中实施前哨节点的影响。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI: 10.1097/CCO.0000000000001074

Ignacio Zapardiel

引用次数: 0

Value of sentinel node ultrastaging and pathologic techniques in tumoral detection. 前哨结节超声造影和病理学技术在肿瘤检测中的价值。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-09-01 Epub Date: 2024-06-12 DOI: 10.1097/CCO.0000000000001061

David Viveros-Carreño, Nathalia Mora-Soto, René Pareja

{"title":"Value of sentinel node ultrastaging and pathologic techniques in tumoral detection.","authors":"David Viveros-Carreño, Nathalia Mora-Soto, René Pareja","doi":"10.1097/CCO.0000000000001061","DOIUrl":"10.1097/CCO.0000000000001061","url":null,"abstract":"Purpose of review: Sentinel lymph node assessment is an option for patients with clinically early-stage vulvar cancer, endometrial cancer, cervical cancer, and, more recently, ovarian cancer. However, although ultrastaging is mandatory as part of the node evaluation, universally accepted pathology protocols are lacking. This review focuses on the current evidence for the most relevant aspects of sentinel lymph node evaluation, as well as some controversial topics like frozen section or one-step nucleic acid amplification.Recent findings: The diagnostic accuracy of sentinel lymph node detection algorithms for patients with gynecologic neoplasms is high. However, the heterogeneity among the published studies and the absence of clear recommendations from most guidelines make it challenging to recommend one protocol over another. The minimum requirement from ultrastaging protocols (regarding the number of levels to be assessed, among others) to get the highest accuracy with a minor cost is unknown.Summary: Sentinel lymph node evaluation is now part of the surgical management for most early-stage gynecologic neoplasms. However, a universally accepted ultrastaging pathology protocol is lacking in literature and clinical practice. This gap requires significant effort from the gynecologic oncology and pathology community to be closed and then to allow advancements in surgical management for early-stage gynecologic tumors to go forward.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"376-382"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to treat advanced Hodgkin lymphoma? 如何治疗晚期霍奇金淋巴瘤？

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-09-01 Epub Date: 2024-06-25 DOI: 10.1097/CCO.0000000000001070

Cédric Rossi, René-Olivier Casasnovas

引用次数: 0

The role of signaling lymphocyte activation molecule family receptors in hematologic malignancies. 信号淋巴细胞活化分子家族受体在血液恶性肿瘤中的作用。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-09-01 Epub Date: 2024-06-19 DOI: 10.1097/CCO.0000000000001067

Louis Boafo Kwantwi, Steven T Rosen, Christiane Querfeld

引用次数: 0

Combination treatment with PD1/PDL-1 inhibitors for sarcomas: state of the art, next questions. 肉瘤的PD1/PDL-1抑制剂联合治疗：最新进展和下一个问题。

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-07-01 Epub Date: 2024-04-30 DOI: 10.1097/CCO.0000000000001050

Javier Martin-Broto, Nadia Hindi, David S Moura

{"title":"Combination treatment with PD1/PDL-1 inhibitors for sarcomas: state of the art, next questions.","authors":"Javier Martin-Broto, Nadia Hindi, David S Moura","doi":"10.1097/CCO.0000000000001050","DOIUrl":"10.1097/CCO.0000000000001050","url":null,"abstract":"Purpose of review: Only a small fraction of sarcomas exhibit recognized parameters of immune sensitivity, such as tumor mutational burden, PDL-1 expression, or microsatellite instability. Combined strategies aimed to modulate tumor microenvironment to increase the efficacy of PD1/PDL-1 inhibitors in sarcoma. Most explored prospective studies were based on combinations of PD1/PDL-1 inhibitors with antiangiogenics, other immune checkpoints, or chemotherapy.Recent findings: Results on 6-month PFS rate, median PFS, and ORR in trials using PD1/PDL-1 inhibitors plus antiangiogenics ranged respectively as 46.9-55%, 4.7-7.8 months and 21-36.7%. In combination with other immune checkpoint inhibitors, the results of median PFS and ORR ranged from 2.8-4.1 months and 10-16%, respectively. In combination with chemotherapy, the best results were obtained with doxorubicin-based regimens compared to other agents. Duplet-based chemotherapy plus anti-PD1/PDL-1 obtained the highest ORR (56.2%) compared with doxorubicin (19-36.7%). Currently, the most robust predictive biomarker for anti-PD1/PDL-1 efficacy is the presence of tertiary lymphoid structures (TLS) with mature dendritic cells.Summary: Even when direct comparisons between PD1/PDL-1 inhibitor-based combinations and single agents have not been performed yet in sarcoma, some combinations appear promising. Studies controlling heterogeneity by biomarker or histotype selection contribute to an increase in efficacy or knowledge crucial for future comparative trials.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"269-275"},"PeriodicalIF":3.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sarculator: how to improve further prognostication of all sarcomas. Sarculator: 如何进一步改善所有肉瘤的预后。

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-07-01 Epub Date: 2024-04-30 DOI: 10.1097/CCO.0000000000001051

Alessandra Borghi, Alessandro Gronchi

{"title":"Sarculator: how to improve further prognostication of all sarcomas.","authors":"Alessandra Borghi, Alessandro Gronchi","doi":"10.1097/CCO.0000000000001051","DOIUrl":"10.1097/CCO.0000000000001051","url":null,"abstract":"Purpose of review: Prognostication of soft tissue sarcomas is challenging due to the diversity of prognostic factors, compounded by the rarity of these tumors. Nomograms are useful predictive tools that assess multiple variables simultaneously, providing estimates of individual likelihoods of specific outcomes at defined time points. Although these models show promising predictive ability, their use underscores the need for further methodological refinement to address gaps in prognosis accuracy.Recent findings: Ongoing efforts focus on improving prognostic tools by either enhancing existing models based on established parameters or integrating novel prognostic markers, such as radiomics, genomic, proteomic, and immunologic factors. Artificial intelligence is a new field that is starting to be explored, as it has the capacity to combine and analyze vast and intricate amounts of relevant data, ranging from multiomics information to real-time patient outcomes.Summary: The integration of these innovative markers and methods could enhance the prognostic ability of nomograms such as Sarculator and ultimately enable more accurate and individualized healthcare. Currently, clinical variables continue to be the most significant and effective factors in terms of predicting outcomes in patients with STS. This review firstly introduces the rationale for developing and employing nomograms such as Sarculator, secondly, reflects on some of the latest and ongoing methodological refinements, and provides future perspectives in the field of prognostication of sarcomas.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"253-262"},"PeriodicalIF":3.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies. 胃肠道恶性肿瘤中 RAS 引导疗法的最新进展和未来趋势。

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-07-01 Epub Date: 2024-04-19 DOI: 10.1097/CCO.0000000000001042

Pieterjan Vanclooster, Sofie Seghers, Hans Prenen

{"title":"State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies.","authors":"Pieterjan Vanclooster, Sofie Seghers, Hans Prenen","doi":"10.1097/CCO.0000000000001042","DOIUrl":"10.1097/CCO.0000000000001042","url":null,"abstract":"Purpose of review: Overall, the review underscores the evolving landscape of KRAS-targeted therapy and the potential for these approaches to improve outcomes for patients with gastrointestinal malignancies. It highlights the importance of ongoing research and clinical trials in advancing precision medicine strategies for KRAS-driven cancers. This review provides a comprehensive overview of the RAS signaling pathway and its significance in gastrointestinal malignancies.Recent findings: The introduction of KRAS inhibitor represents a significant advancement in the treatment landscape for KRAS-mutant cancers. In this review, we discuss upcoming trends in KRAS-targeted therapy, including the development of mutant-specific direct KRAS inhibitors like MRTX1133 and pan-RAS inhibitors such as RMC-6236. It also explores indirect RAS inhibitors targeting upstream and downstream components of the RAS pathway. Additionally, the review examines other upcoming strategies like combination therapies, such as CDK4/6 and ERK MAPK inhibitors, as well as adoptive cell therapy and cancer vaccines targeting KRAS-mutant cancers.Summary: Targeting RAS has become an important strategy in treating gastrointestinal cancer. These findings in this review underscore the importance of a multidisciplinary approach, integrating advances in molecular profiling, targeted therapy, immunotherapy, and clinical research to optimize treatment strategies for patients with KRAS-mutant gastrointestinal malignancies.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"313-319"},"PeriodicalIF":3.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0